Clinical Overview
Lofepramine is a tricyclic antidepressant primarily available in European markets, indicated for the treatment of depression. It is considered one of the safer tricyclic antidepressants with lower cardiotoxicity in overdose compared to other TCAs, making it a preferred choice when tricyclic therapy is indicated.
Primary Clinical Applications
Lofepramine is indicated for major depressive disorder, particularly in patients who may benefit from tricyclic therapy but require a safer profile. It is effective for both typical and atypical depression and may be particularly useful in patients with anxiety accompanying their depression.
Mechanism and Safety Profile
Like other tricyclics, lofepramine blocks norepinephrine and serotonin reuptake, but it has reduced anticholinergic effects and lower cardiotoxicity compared to traditional TCAs. This improved safety profile makes it suitable for patients who cannot tolerate other tricyclics or are at higher risk for overdose.
Clinical Advantages
Lofepramine offers the efficacy of tricyclic antidepressants with improved tolerability and safety. It has less sedation, fewer anticholinergic effects, and significantly lower risk of fatal overdose compared to other TCAs, while maintaining therapeutic effectiveness for depression.
Prescribing Information
Dosing & Administration
Depression – Adults:
- Initial: 70 mg twice daily (140 mg daily)
- Range: 140-210 mg daily in divided doses
- Maximum: 210 mg daily
- Maintenance: Usually 70-140 mg daily
Elderly:
- Initial: 35-70 mg daily
- Maintenance: 70-105 mg daily
- Titrate slowly based on response and tolerance
Administration:
- Divide daily dose into 2-3 administrations
- Take with food to reduce GI upset
- Consistent timing each day
Indications
- Treatment of depression
- Particularly suitable when tricyclic therapy is indicated but safety is a concern
Contraindications
- Hypersensitivity to lofepramine or tricyclic antidepressants
- Recent myocardial infarction
- Concurrent MAOI use (within 14 days)
- Severe liver disease
Warnings & Precautions
- Suicidal risk: Monitor for increased suicidal thoughts, especially in young adults
- Cardiovascular effects: Lower risk than other TCAs but still monitor in cardiac patients
- Seizure risk: May lower seizure threshold
- Anticholinergic effects: Reduced compared to other TCAs but still present
- Withdrawal: Taper gradually to avoid discontinuation syndrome
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CNS depressants: Enhanced sedation
- Anticholinergic drugs: Additive anticholinergic effects
- CYP2D6 inhibitors: May increase lofepramine levels
Adverse Reactions
Common:
- Dry mouth, constipation, drowsiness, dizziness
- Sweating, tremor, blurred vision
Advantages over other TCAs:
- Lower incidence of anticholinergic effects
- Reduced cardiotoxicity
- Safer in overdose
Special Populations
- Elderly: Start with lower doses, monitor for anticholinergic effects
- Cardiac Disease: Safer than other TCAs but still requires monitoring
- Pregnancy: Category C – use only if benefits outweigh risks
- Overdose Safety: Significantly safer than other tricyclics
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
